Mucormycosis of the bones of the facial skull, nasal cavity and par anasal sinuses in patients with COVID19
Open Access
- 1 January 2021
- journal article
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 23 (4)
- https://doi.org/10.36488/cmac.2021.4.347-358
Abstract
Currently, the relevance of the issues of diagnosis and treatment of invasive fungal diseases has increased significantly due to the pandemic of a new coronavirus infection COVID-19 and the massive use of corticosteroids for the treatment. The key success factors in the outcome of invasive fungal diseases are early diagnosis and treatment, including the applying of an adequate systemic antifungal therapy and surgical treatment. Extensive areas of mycotic lesions of the facial bones and paranasal sinuses are lifethreatening conditions due to anatomical proximity to brain structures and a high risk of dissemination of I invasive fungal diseases with a fatal outcome. The objective of this work was to study the risk factors, possible pathogenesis, diagnosis and treatment strategy of invasive fungal diseases of the orofacial region in convalescents of COVID-19. We present case-series data on six patients in the clinics of maxillofacial surgery and otorhinolaryngology of the Pavlov First Saint Petersburg State Medical University over the period of 2021–2022. Predisposing factors, clinical and radiological symptoms, features of diagnosis, therapy and surgical strategy were analyzed. The presented observations confirm the relevance and danger of complications after a COVID-19 in the form of the development of invasive fungal diseases with damage to the maxillofacial region caused by mucormycetes and Aspergillus spp., as well as importance of early diagnosis and treatment.Keywords
This publication has 61 references indexed in Scilit:
- Procalcitonin Identifies Cell Injury, Not Bacterial Infection, in Acute Liver FailurePLOS ONE, 2015
- Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge dataBMC Infectious Diseases, 2014
- Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile InfectionAntimicrobial Agents and Chemotherapy, 2013
- Impact of the 2009 Influenza Pandemic on Pneumococcal Pneumonia Hospitalizations in the United StatesThe Journal of Infectious Diseases, 2011
- Mortality in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients with Mucormycosis, 2001 to 2009Antimicrobial Agents and Chemotherapy, 2011
- Bacterial Coinfections in Lung Tissue Specimens from Fatal Cases of 2009 Pandemic Influenza A (H1N1) – United States, May–August 2009The Pediatric Infectious Disease Journal, 2010
- Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza PreparednessThe Journal of Infectious Diseases, 2008
- Bacterial Pneumonia and Pandemic Influenza PlanningEmerging Infectious Diseases, 2008
- Polymorphic Ventricular Tachycardia with a Normal QT Interval Following AzithromycinPacing and Clinical Electrophysiology, 2005
- QT Prolongation with Antimicrobial AgentsDrugs, 2004